Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

Robert Dreicer, MD
Published: Monday, Mar 21, 2016



Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.

Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.

<<< View more from 2016 New York GU



Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 makes for an interesting compound because, unlike many other therapies in the field, it is not androgen receptor (AR)-directed, Dreicer explains. The agent is approved before or after treatment with docetaxel for patients with predominant bone metastases. Because of this, it is a useful therapy for select patients.

Currently, researchers are questioning how to properly integrate radium-223 with AR therapies. Therefore, the optimal use of radium-223 in patients with mCRPC is not yet defined, Dreicer concludes.

<<< View more from 2016 New York GU


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x